Slide 1: Corporate Presentation, Oct 2016
For personal use only Corporate Presentation, Oct 2016 ASX: NOX 1
Slide 2: In a nutshell
In a nutshell…..... For personal use only In 1971, cancer researchers dreamt of turning cancer into a manageable, non-lethal, chronic disease 45 years later that dream remains elusive for most types of cancer In 1971, chemotherapy and radiotherapy were the standard frontline therapies 45 years later
Slide 3: In a nutshell
In a nutshell…..... For personal use only The dream remains elusive because chemotherapy and radiotherapy are not being used to their full powers …. because damage to healthy cells dictates the highest dose of chemo and radiotherapy that can be used, and that dose is not enough to kill all cancer ce
Slide 4: Noxopharm believes it has the answer
Noxopharm believes it has the answer…..... For personal use only IDRONOXIL: sensitises cancer cells (and only cancer cells) to standard chemotherapy and radiotherapy IDRONOXIL : dramatic level of sensitisation >2000x NOX66: delivering IDRONOXIL in a form designed to maintain its activity in the body
Slide 5: Cancer metrics
Cancer metrics For personal use only 45 years later 1971: 2016: President Richard Nixon signs The war Vice-President Joe Biden National Cancer Act continues Announces “Cancer moonshot” Declares “War on cancer” 5
Slide 6: After years of 'the war on cancer'
After After 45 45 years Years of of ‘the warChemotherapy... Cytotoxic on cancer’….... For personal use only 10-year survival rates remain poor for many cancers • Pancreas Little or no • Lung progress • Brain made in • Head and neck survival • Oesophagus outcome for • Stomach cancers of: • Cervix • B
Slide 7: Frontline cancer therapies work by damaging DNA
Frontline cancer therapies work by damaging DNA For personal use only Radiotherapy Chemotherapy Aim is to damage DNA beyond repair cell dies 7
Slide 8: The problem
The problem For personal use only alive Normal cells MAXIMUM TOLERABLE DOSE Highest dose of chemotherapy or radiotherapy that can be delivered is killed determined by the highest dose that can be tolerated by the patient. 8
Slide 9: The problem: Maximum Tolerated Dose leaves many cancer cells alive
The problem For personal use only The Maximum Tolerated Dose leaves many cancer cells alive High cancer kill eg. cancers of breast, ovary Regardless of cancer type: Normal surviving cancer cells regrow cells Cancer cells to form new, more aggressive cancer Max tolerated dose Low cancer kill eg. canc
Slide 10: The solution
The solution For personal use only To sensitise cancer cells (and only cancer cells) Normal cells Cancer to DNA-damaging effects of cells chemotherapy and radiotherapy so that ALL cancer cells are killed 10
Slide 11: The answer
The answer For personal use only Sensitises all forms of cancer cells (but not healthy cells) by > 2,000x Idronoxil to all standard cytotoxic chemotherapy drugs and radiotherapy 11
Slide 12: Idronoxil history
Idronoxil history History Idronoxil For personal use only Named phenoxodiol. Basis of formation of Discovered in 1992 Novogen Ltd Potent ability to (ASX:1994). sensitise chemotherapy confirmed Phase III study Evidence of anti-cancer (phenoxodiol + Novogen market cap = benefits observed in Enters cli
Slide 13: The Problem: Phase 2 metabolism
The Problem: Idronoxil Phase failed because of 2 Metabolism Phase 2 metabolism For personal use only Body attaches sugar to allow drug to be excreted in urine Drug rendered INACTIVE 13
Slide 14: The solution: NOX66
The The Problem: solution: Phase 2 Metabolism NOX66 For personal use only Body prevented from attaching sugar Drug remains in ACTIVE form 14
Slide 15: Clinical Program
Clinical Program For personal use only Cytotoxic chemotherapy Radiotherapy 15
Slide 16: Clinical strategy
Clinical strategy For personal use only To run a broad clinical trials program designed to identify: • chemotherapy 1. The best treatment combination • radiotherapy 2. The best purpose of us • Make standard doses work better • Allow use of lower doses 3. Optimal cancer type • Prostate, breast, lung,
Slide 17: And to have that decision by end-2017
And to have that decision by end-2017 For personal use only Proposed clinical study timeline 4Q 2016 1Q 2017 2Q 2017 3Q 2017 4Q 2017 1Q 2018 Chemotherapy Study Phase 1a Phase 1b Phase 2a Radiotherapy Study 1 Phase 1b/2a Phase 1b/2a Radiotherapy Study 2 17
Slide 18: Cancer metrics
Cancer metrics For personal use only Annual spend on anti-cancer drugs = >US$100 billion Top 10 anti-cancer drugs = US$45 billion What value a drug that would have a rationale for use in most patients? 18
Slide 19: Our objective
Our objective For personal use only To bring to market the first drug that sensitises cancer cells to cancer therapies to improve the survival outcomes of standard chemotherapy and radiotherapy and allow effective dosages of standard chemotherapy and radiotherapy to be lowered to non-toxic levels an
Slide 20: Clinical studies
Clinical studies For personal use only Patients with late-stage cancers that have failed to respond to standard therapies and have no remaining standard treatment options Q1. Can NOX66 result in a significant anti-cancer response where none is expected? Q2. Can Q1. Can NOX66 NOX66 result allow in do
Slide 21: Indicative timelines
Indicative timelines For personal use only Proposed clinical study timeline 4Q 2016 1Q 2017 2Q 2017 3Q 2017 4Q 2017 1Q 2018 Chemotherapy Study Phase 1a Phase 1b Phase 2a Radiotherapy Study 1 Phase 1b/2a Phase 1b/2a Radiotherapy Study 2 21
Slide 22: IP position
IP position For personal use only Idronoxil Structure not patentable. First described by G. Kelly in 1994. Patent lodgement Family of provisional patents lodged. Claims revolve around innovative formulation designed to block Phase 2 metabolism and conserve bio-activity 2nd and 3rd generation R&D pro
Slide 23: Experienced team
Experienced team For personal use only Experienced Team Graham Kelly PhD Dr Ian Dixon PhD, MBA Managing Director Non-Executive Director •Head of research team at University of Sydney that discovered idronoxil in 1992 •Over 20 years’ experience in the biotechnology and medical device industries and •
Slide 24: Key metrics
Key metrics For personal use only Shares outstanding 75M 30M free; 45M escrowed (July 2019) Other 22.5M options ($0.30) (2021) 10M performance shares ($50M market cap) (2021) Cash position $6M IPO (9 Aug 2016) $5M (Sept 2016) Budgeted to take Company to proof-of-concept stage 24
Slide 25: Value drivers
Value DriversValue drivers For personal use only Large Lack of Clinic- Expeditious market size competition Experience ready clinical plan No current drug or known drug Over 20 years’ Substantial Indication of in development experience with unmet need for Phase 1 study efficacy with same this technol
Slide 26: Key Messages
For personal use only Key Messages Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing patients No drug has come to market that successfully treats this problem WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION IN RADIOTHERAPY WE EXPECT TO KNOW
Slide 27: Disclaimer
For personal use only Disclaimer 4 This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 28: Contact
For personal use only Contact Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 28